Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer  receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.

Head and neck squamous cell cancer is relatively uncommon in the United States compared to other malignancies like non-small–cell lung cancer and breast cancer. There are about 500,000 cases worldwide every year.

Review of the currently available and approved therapeutic agents for the management of metastatic squamous cell NSCLC and clinical trials focusing on targeted therapy.